It is noteworthy that studies have suggested that certain PPAR agonist (thiazolidinedione) can inhibit NF-κB DNA binding, offering a new therapeutic strategy for lymphoblastic leukemia and IBD.581,582. Here, NFKB1 is linked to inflammatory bowel disease.